Peter Geschek
Long only

Small Esperion Vs. Pharma Giants In The Cholesterol Race

Esperion Therapeutics (NASDAQ:ESPR), a tiny, Plymouth, Mich based developer of cholesterol drugs, recently started Phase 2b trials of its compound ETC-1002. The trial enrolls people who cannot tolerate statins and/or have high LDL-C (bad cholesterol) levels that they cannot control.

ETC-1002 is a once-daily, oral, small molecule drug that lowers the level of LDL-C and avoids the side effects caused by statins.

The goal of the trial is to compare the LDL-C lowering efficacy of ETC-1002 taken with ezetimibe and to demonstrate that it is as tolerable as ezetimibe. Ezetimibe is a drug commonly used for statin intolerance. A patient is considered statin intolerant if he or she cannot tolerate two or more statins administered at or below...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details